QT Holdings Corp. announced a collaboration with Sartorius Stedim Biotech. This partnership will enable worldwide availability of a magnetic bead-free T cell activation product built with Quad Technologies’ patented QuickGel platform. According to Quad Technologies Co-Founder & CEO Sean Kevlahan, this partnership promises to greatly expand the reach of the company’s revolutionary product and support global cell therapy development and manufacturing. The agreement marks Quad Technologies’ first global partnership and signals an era of rapid growth for the innovative Massachusetts-based company. Kevlahan sees this as a major step in his mission to offer every corner of the globe a full range of disruptive workflow solutions spanning the entire cell therapy manufacturing process. The exclusive deal covers a brand new QuickGel-based product that enables CD3 and CD28-mediated T cell activation, which is expected to begin shipping in 2018 in both in Research and cGMP grades.